News | February 02, 2022
Panacea Biotec sells its domestic formulations business to Mankind Pharma
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
The aim is to support Pharmacovigilance programme across the countries in the region
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
The focus is on wellness and personal care products
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
